Top Players in the Generic Injectables Market

Top Players in the Generic Injectables Market

The global generic injectables market reached a value of US$ 47.5 Billion in 2023. As per the analysis by IMARC Group, the top generic injectables companies are increasingly focusing on various research and development (R&D) activities to develop complex and differentiated products. For instance, the number of competitors in the generic injectables market is lower than in oral generics, resulting in limited price erosion and significantly high-profit margins for manufacturers In the GCC region. Moreover, several branded injectables in the European region are anticipated to lose their patient protection in the upcoming years, thereby offering numerous remunerative opportunities to the generic injectables manufacturers. In India, the shortage of branded medicine and the expiry of patents of branded items have prompted manufacturers to introduce advanced drug delivery systems, including self-injection devices. On account of these factors, the market to reach US$ 90.9 Billion by 2032, exhibiting at a CAGR of 7.2% during 2024-2032.

Request Free Sample Report:

List of the Top Generic Injectables Companies Worldwide:

Hospira (Pfizer Inc.)

Establishment: 2004
Headquarter: Illinois, United States

Hospira is one of the world’s leading providers of injectable drugs. It was acquired by Pfizer by entering into a definitive merger agreement. The company boasts a broad portfolio of generic injectable drugs, which are in high demand. Hospira is equipped with enhanced commercial capabilities, scientific expertise, and manufacturing prowess at a global scale. It also includes two of the largest sterile injectable manufacturing facilities in the world, aimed at maximizing the global potential of its enhanced GEP portfolio of sterile injectables, biosimilars, and medication management systems.

Fresenius Kabi AG

Establishment: 1999
Headquarters: Bad Homburg, Germany

Fresenius Kabi AG is a global healthcare company specializing in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. The product portfolio of the company comprises a wide range of intravenous (IV) generic drugs, infusion therapies, and clinical nutrition products as well as devices for administering these products, aimed to help critically and chronically ill patients. Furthermore, Fresenius Kabi AG has launched biosimilars to focus on autoimmune diseases and oncology. In transfusion medicine and cell therapies, the company offers products to collect blood components and extracorporeal therapies.

Hikma Pharmaceuticals plc

Establishment: 1978
Headquarter: London, United Kingdom

Hikma pharmaceuticals were established as a supplier of branded generics and in-licensed products. It develops and manufactures high-quality medicine, making them accessible to people who need them. The company is also working toward a broad product range and a growing pipeline of new medicines, including the anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory therapeutics. In addition, it supplies various generic drugs such as anesthetics, pain medications, sedatives, and neuromuscular blocking agents. Currently, Hikma has a differentiated US portfolio of close to 130 injectable medicines.

Sandoz International GmbH (Novartis International AG)

Establishment: 1996
Headquarters: Basel, Switzerland

Sandoz International GmbH aims at discovering new ways to improve and extend the lives of people. It pioneers novel approaches to help patients around the world access high-quality medicine. The company also pursues an integrated access strategy that focuses on improving access to medicines, medical information, and access to medical capacity building. By 2019, the company has reached over 500 million patients worldwide. It is one of the foremost players in biosimilars, generic antibiotics, and generic oncology injectables. Moreover, the company’s portfolio is backed by a range of state-of-the-art technologies, formulations, and devices, including prolonged-release, multiple-unit tablets, creams and gels, orodispersible films, and transdermal patches, lyophilized products, implants, and inhalers.

Sagent Pharmaceuticals, Inc. (Nichi-Iko Pharmaceutical Co. Ltd.)

Establishment: 2007
Headquarter: Illinois, United States

Sagent Pharmaceuticals manufactures and distributes generic injectables in the US. It is a customer-focused company that delivers an extensive portfolio of injectable products and fulfills the evolving needs of the patients. Sagent pharmaceuticals also provide the essential specialty injectable products and offer multiple packaging options from premix bags and prefilled syringes to single-dose vials and pharmacy bulk package vials. Moreover, the company aims at delivering the products in a timely manner, ensuring consistency of supply, quality, and service. Most importantly, they strive to reduce medication errors and improve patient safety by designing enhanced product labels and packaging that feature easy-to-read product names, dosage strengths, and bar codes.

Sanofi S.A.

Establishment: 2004
Headquarters: Paris, France

Sanofi has led the science in immunology by introducing new treatment options for chronic, difficult-to-treat inflammatory diseases such as atopic dermatitis (eczema), asthma, and rheumatoid arthritis. The company is applying the most advanced research technologies and is focused on treating inflammatory conditions and autoimmunediseases with the highest unmet need. One of its key approaches is to develop multi-specific antibody therapies that combine multiple mechanisms of action in a single molecule and simultaneously target two or more molecular pathways.

Baxter International Inc.

Establishment: 1931
Headquarter: Illinois, United States

Baxter is an American multinational health care company that manufactures and distributes generic injectables across the United States. It offers a portfolio with a broad range of high-quality essential medicines. The company caters to products and therapies that can be found throughout hospitals and clinics, from the emergency to operating room, pharmacy to the ICU, and advancing patients’ care in their homes. Baxter has announced acquisition with India’s Claris Injectables and made a deal with Taiwan-based active pharmaceutical ingredient (API) maker ScinoPharm. These acquisitions are expected to widen the portfolio of essential generics, including anesthetics and analgesics, renal, anti-infectives, and critical care medicines. They have also developed, manufactured, and commercialized some generic injectables used in cancer treatment.


About IMARC Group: IMARC Group is a leading market research and consulting company that offers management strategy and market research worldwide. The company has done multiple projects on the global generic injectables and regional Latin America, industry, which has enabled clients to set up and expand their businesses successfully. Some of the company’s offerings include:

  • Market Research
  • Plant setup
  • Plant Expansion
  • Marketing and sales
  • Procurement and Distribution
  • Innovation and Product Development

For more information on this market, write to us:

Please enter the Captcha text*

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-713-2163